JohnThomasCallaghanMD

PubMed

• 1 citations
  The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.
  Michael T Eadon, Marc B Rosenman, Pengyue Zhang, Cathy R Fulton, John T Callaghan, Ann M Holmes, Kenneth D Levy, Samir K Gupta, David M Haas, Raj Vuppalanchi, Eric A B...> ;The Pharmacogenomics Journal. 2023 Nov 1
• 5 citations
  Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid Cancers.
  Tyler Shugg, Reynold C Ly, Elizabeth J Rowe, Santosh Philips, Mustafa A Hyder, Milan Radovich, Marc B Rosenman, Victoria M Pratt, John T Callaghan, Zeruesenay Desta, B...> ;JCO Precision Oncology. 2022 Feb 1
• Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer.
  Elizabeth J Rowe, Tyler Shugg, Reynold C Ly, Santosh Philips, Marc B Rosenman, John T Callaghan, Milan Radovich, Brian R Overholser, Bryan P Schneider, James E Tisdale...> ;Frontiers in Cardiovascular Medicine. 2022 Jan 1
• 170 citations
  Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy.
  Kristine R. Crews, Andrew A. Monte, Rachel Huddart, Kelly E. Caudle, Evan D. Kharasch, Andrea Gaedigk, Henry M. Dunnenberger, J. Steven Leeder, John T. Callaghan, Caro...> ;Clinical Pharmacology and Therapeutics. 2021 Oct 1
• 1 citations
  Response to Gammal et al.
  Jason L. Vassy, Annjanette Stone, John T. Callaghan, Margaret A.S. Mendes, Laurence Meyer, Victoria M. Pratt, Ronald M. Przygodzki, Maren T. Scheuner, Jessica Wang-Rod...> ;Genetics in Medicine. 2019 Jan 12
• 42 citations
  Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.
  Michael T. Eadon, Zeruesenay Desta, Kenneth D. Levy, Brian S. Decker, Rebecca C. Pierson, Victoria M. Pratt, John T. Callaghan, Marc B. Rosenman, Janet S. Carpenter, A...> ;Clinical Pharmacology and Therapeutics. 2016 Jul 1
• 7 citations
  Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers
  Zeruesenay Desta, Ingrid F. Metzger, Nancy Thong, Jessica Bo Li Lu, John T. Callaghan, Todd C. Skaar, David A. Flockhart, Raymond E. Galinsky> ;Antimicrobial Agents and Chemotherapy. 2016 Nov 1
• 63 citations
  Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
  Milan Radovich, Patrick J. Kiel, Stacy Marie Nance, Erin Niland, Megan E. Parsley, Meagan E. Ferguson, Guanglong Jiang, Natraj Reddy Ammakkanavar, Lawrence H. Einhorn,...> ;Oncotarget. 2016 Jul 15
• 98 citations
  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update
  Yoshiro Saito, Lisa K. Stamp, Kelly E. Caudle, Hershfield, Ellen M. McDonagh, J T Callaghan, Wongwiwat Tassaneeyakul, T Mushiroda, Naoyuki Kamatani, Barry R. Goldspiel...> ;Clinical Pharmacology and Therapeutics. 2016 Jan 1
• 8 citations
  Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.
  Troy C. Quigg, Noam Epstein, Abdulateef O. Aregbe, Nancy Thong, John T. Callaghan, David A. Flockhart, Anne T. Nguyen, Colleen K. Stevens, Samir K. Gupta, Zeruesenay D...> ;Current Therapeutic Research, Clinical and Experimental. 2014 Dec 1
• 155 citations
  Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
  Kelly E. Caudle, Allan E. Rettie, Michelle Whirl-Carrillo, L H Smith, Scott Mintzer, Ming Ta Michael Lee, Teri E. Klein, John T. Callaghan> ;Clinical Pharmacology and Therapeutics. 2014 Nov 1
• 30 citations
  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.
  Ellen M. McDonagh, Caroline F. Thorn, John T. Callaghan, Russ B. Altman, Teri E. Klein> ;Pharmacogenetics and Genomics. 2014 Sep 1
• 442 citations
  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
  Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger, J. S. Leeder, Teri E. Klein, Kelly E. Caudle, Cyrine E. Haidar, Danny D. Shen, J T Callaghan, Senthilkumar Sa...> ;Clinical Pharmacology and Therapeutics. 2014 Apr 1
• 154 citations
  Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing
  Michael S. Hershfield, J T Callaghan, Wichittra Tassaneeyakul, T Mushiroda, Caroline F. Thorn, Teri E. Klein, Ming Ta Michael Lee> ;Clinical Pharmacology and Therapeutics. 2013 Feb 1
• 261 citations
  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype
  Kristine R. Crews, Andrea Gaedigk, Henry M. Dunnenberger, Teri E. Klein, Danny D. Shen, J T Callaghan, Evan D. Kharasch, Todd C. Skaar> ;Clinical Pharmacology and Therapeutics. 2012 Feb 1
• 12 citations
  A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies
  Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert J. Gazak, John T. Callaghan, Daniel D. Von Hoff, ...> ;Clinical Cancer Research. 2003 Nov 15
• 395 citations
  Olanzapine. Pharmacokinetic and pharmacodynamic profile.
  John T. Callaghan, Richard F. Bergstrom, Louis R. Ptak, Charles M. Beasley> ;Clinical Pharmacokinetics. 1999 Sep 1
• 12 citations
  Lack of Effect of Olanzapine on the Pharmacokinetics of a Single Aminophylline Dose in Healthy Men
  William L. Macias, Richard E Bergstrom, Benito J. Cerimele, Kelem Kassahun, David E. Tatum, John T. Callaghan> ;Pharmacotherapy. 1998 Nov 12
• 22 citations
  Olanzapine: Interaction study with imipramine
  John T. Callaghan, Benito J. Cerimele, Kelem J. Kassahun, Eldon H. Nyhart, Pamela J. Hoyes-Beehler, George V. Kondraske> ;Journal of Clinical Pharmacology. 1997 Oct 1
• Inhibition of dihydropyrimidine dehydrogenase by 5-propynyluracil, a metabolite of the anti-varicella zoster virus agent netivudine.
  Peck R, Wiggs R, Callaghan J, Wootton R, Crome P, Fraser I, Frick L, Posner J> ;Clin. Pharmacol. Ther.. 1996-01-01
• 10 citations
  Secretion of nizatidine into human breast milk after single and multiple doses.
  Boyd D Obermeyer, Richard F. Bergstrom, John T. Callaghan, Mary Pat Knadler, Alan Golichowski, Alan Rubin> ;Clinical Pharmacology and Therapeutics. 1990 Jun 1
• 22 citations
  Nizatidine disposition in subjects with normal and impaired renal function
  George R. Aronoff, Richard F. Bergstrom, Ronald J Bopp, Rebecca S. Sloan, John T. Callaghan> ;Clinical Pharmacology and Therapeutics. 1988 Jun 1
• 21 citations
  Absorption studies of the H2-blocker nizatidine
  Mary Pat Knadler, Richard F. Bergstrom, John T. Callaghan, Boyd D. Obermeyer, Alan Rubin> ;Clinical Pharmacology and Therapeutics. 1987 Nov 1
• 12 citations
  Nizatidine, an H2-receptor antagonist: disposition and safety in the elderly
  John T. Callaghan, Alan Rubin, Mary Pat Knadler, Richard F. Bergstrom> ;Journal of Clinical Pharmacology. 1987 Aug 1
• Intravenous nizatidine kinetics and acid suppression.
  Callaghan JT, Bergstrom RF, Obermeyer BD, King EP, Offen WW> ;Clin. Pharmacol. Ther.. 1985-02-01
• Join now to see all

Journal Articles

• Pharmacogenetic Testing in the Veterans Health Administration (VHA): Policy Recommendations from the VHA Clinical Pharmacogenetics Subcommittee  
  Jason L Vassy, Steven A Schichman, John T Callaghan, Nature